STOCK TITAN

Align Technology Announces Fourth Quarter and Fiscal 2023 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Align Technology, Inc. reported Q4 and FY2023 total revenues up 6.1% and 3.4% year over year, respectively. Major milestones include 17 million Invisalign patients, 4 million Vivera retainers, and 100 thousand iTero scanner units sold in 2023. The company's 2023 total revenues were $3.9 billion, with clear aligner revenues of $3.2 billion and systems and services revenues of $662.9 million. The 2023 operating margin was 16.7%, with non-GAAP operating margin of 21.4%. The company repurchased $600 million of common stock in 2023. Q4'23 total revenues were $956.7 million, down 0.4% sequentially and up 6.1% year-over-year. Clear Aligner revenues were $781.9 million, down 1.6% sequentially and up 6.9% year-over-year. The company also unveiled the iTero Lumina intraoral scanner with significant improvements in scanning capabilities.
Positive
  • None.
Negative
  • None.

Insights

The reported financial results from Align Technology, Inc. reflect a nuanced picture of the company's performance, with a mix of positive growth indicators and challenges influenced by foreign exchange rates. The year-over-year revenue increase of 6.1% and the 3.4% rise for the full fiscal year suggest a resilient demand for the company's products, particularly the Invisalign system, despite a slight decline in clear aligner shipments. This resilience in demand is a positive signal for investors, indicating the company's strong market position and effective product diversification strategy.

However, the impact of foreign exchange on revenues and operating margins indicates the global nature of Align's business and the susceptibility of its financials to currency fluctuations. The reported unfavorable foreign exchange impact of approximately $36.3 million on 2023 revenues highlights the importance for investors to consider currency risks when evaluating the company's performance. The operating margin improvements, both GAAP and non-GAAP, are noteworthy as they suggest effective cost management and operational efficiency. The repurchase of $600 million of common stock signals confidence in the company's future growth prospects and a shareholder-friendly capital allocation policy.

The introduction of the iTero Lumina intraoral scanner represents a strategic move to solidify Align's competitive edge in the dental equipment market. The scanner's advanced features, such as a 3X wider field of capture and a 50% smaller wand, are designed to enhance practice efficiency and patient comfort, potentially leading to increased adoption rates among dental professionals. The filing of over 30 patent applications covering technology related to the iTero Lumina scanner underscores the company's commitment to innovation and intellectual property protection, which can be a critical driver of long-term value creation for shareholders.

Furthermore, Align's strategic growth drivers, including international expansion and increased utilization among orthodontists and general practice dentists, suggest a forward-looking approach to capturing a larger share of the orthodontic market. The potential untapped market opportunity of 22 million annual orthodontic case starts, coupled with the broader consumer market for dental health and aesthetics, provides a substantial runway for growth. The company's capital expenditure plans for 2024, amounting to approximately $100 million, reflect ongoing investments in infrastructure and manufacturing capacity to support this expansion.

The medical device sector, particularly within orthodontics and dental equipment, is highly sensitive to technological advancements and product innovation. Align's launch of the iTero Lumina intraoral scanner is a critical development within this context. The scanner's technical capabilities, such as increased scanning speed, higher accuracy and improved visualization, are tailored to meet the evolving needs of dental practices. Such advancements not only improve the patient experience but also streamline the workflow for practitioners, potentially leading to higher productivity and profitability for practices that adopt this technology.

The company's continued investment in research and development, as evidenced by the Research Award Program and the acquisition of Cubicure GmbH, indicates a commitment to maintaining a pipeline of innovative products. This strategy is essential for sustaining long-term growth in a competitive market where technological obsolescence can quickly diminish a company's market share. Align's focus on innovation is likely to positively influence its market position and financial performance, making it a key factor for stakeholders to monitor.

Unveils Next-Generation iTero Lumina™ Intraoral Scanner Featuring a 3X Wider Field of Capture1 in a 50% Smaller Wand2 that Delivers Faster Scanning, Higher Accuracy3, and Superior Visualization4 for Greater Practice Efficiency

Q4 and FY2023 total revenues up 6.1% year over year and up 3.4% year over year, respectively

Major 2023 milestones: 17 million Invisalign® patients, 4 million Vivera™ retainers, and 100 thousand iTero™ scanner units

  • 2023 total revenues of $3.9 billion, Clear Aligner revenues of $3.2 billion and Systems and Services revenues of $662.9 million
  • 2023 revenues were unfavorably impacted by foreign exchange of approximately $36.3 million compared to 2022(5)
  • 2023 operating margin of 16.7%, non-GAAP operating margin of 21.4%, and diluted net income per share of $5.81, non-GAAP diluted net income per share of $8.61
  • 2023 operating margin was favorably impacted by foreign exchange of approximately 0.7 points compared to 2022(5)
  • Repurchased $600 million of common stock in 2023
  • Q4 total revenues of $956.7 million, and diluted net income per share of $1.64, non-GAAP diluted net income per share of $2.42
  • Q4 revenues were unfavorably impacted by foreign exchange of approximately $12.8 million sequentially and favorably impacted by approximately $13.8 million year over year(5)

TEMPE, Ariz.--(BUSINESS WIRE)--

Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the fourth quarter ("Q4'23") and year ended December 31, 2023 ("2023"). Q4'23 total revenues were $956.7 million, down 0.4% sequentially and up 6.1% year-over-year. Q4'23 Clear Aligner revenues were $781.9 million, down 1.6% sequentially and up 6.9% year-over-year. Q4'23 Clear Aligner volume was down 1.6% sequentially and down 0.6% year-over-year. Q4'23 Imaging Systems and CAD/CAM Services revenues were $174.8 million, up 5.8% sequentially and up 2.9% year-over-year. Q4’23 Clear Aligner revenues were unfavorably impacted by foreign exchange of approximately $10.7 million or 1.4% sequentially and favorably impacted by approximately $12.0 million or 1.6% year over year.(5) Q4'23 Imaging Systems and CAD/CAM Services revenues were unfavorably impacted by foreign exchange of approximately $2.1 million or 1.2% sequentially and favorably impacted by approximately $1.9 million or 1.1% year over year.(5) Q4'23 operating income was $171.5 million resulting in an operating margin of 17.9%. Q4'23 operating margin was unfavorably impacted by foreign exchange of approximately 0.6 points sequentially and favorably impacted by approximately 0.6 points year over year.(5) Q4'23 net income was $124.0 million, or $1.64 per diluted share. On a non-GAAP basis, Q4'23 net income was $183.5 million, or $2.42 per diluted share.

2023 Clear Aligner revenues of $3.2 billion were unfavorably impacted by foreign exchange of approximately $29.7 million or 0.9% compared to 2022.(5) 2023 Imaging Systems and CAD/CAM Services revenues of $662.9 million were unfavorably impacted by foreign exchange of approximately $6.6 million or 1.0% compared to 2022.(5) During Q4’23, we incurred a total of $14.0 million of restructuring and other charges, primarily related to post-employment benefits.

Commenting on Align's Q4'23 and 2023 results, Align Technology President and CEO Joe Hogan said, “I am pleased to report fourth quarter results with better-than-expected revenues and earnings, primarily reflecting a sequential increase in clear aligner volume for adults and non-comprehensive cases, growth in Canada and the EMEA region, as well as increased revenues from systems and services. Fourth quarter revenues were up year-over-year primarily reflecting an increase in clear aligner volumes for teens and Invisalign DSP touch-up cases, as well as growth in the EMEA and APAC regions. For fiscal 2023, total revenues were up year over year, and we delivered fiscal 2023 non-GAAP operating margin above 21%, as expected. As of Q4, we achieved 17 million Invisalign® patients—including 4.7 million teens, as well as 4 million Vivera™ retainer cases, and over 100 thousand iTero™ scanners sold."

Hogan continued by announcing the launch of the company's latest iTero Lumina scanner, "Today, I’m excited to unveil a breakthrough technology — the iTero Lumina™ intraoral scanner - with 3X wider field of capture in a 50% smaller wand that delivers faster scanning, higher accuracy, and superior visualization for greater practice efficiency. iTero Lumina quickly, easily, and accurately captures more data while delivering exceptional scan quality and photorealistic visuals that remove the need for intraoral photos altogether. Doctors can now scan at twice the speed with a wide field of capture, multi angled scanning, and a large capture distance, meaning they can capture more dentition in greater detail throughout the scanning process. Align has filed over 30 patent applications covering technology related to the iTero Lumina intraoral scanner. I believe iTero Lumina has the potential to set a new standard of care for dental practices by simplifying the scanning of complex oral regions, while offering superior chair-side visualization and a more comfortable experience for patients, especially kids.”

(1) Compared to the field of view of the iTero Element™ 5D imaging system, when the iTero Lumina™ intraoral scanner’s scanning distance is 12 mm.*
(2) Compared to iTero Element™ 5D imaging system wand, excluding the wand cable.*
(3) The iTero Lumina™ intraoral scanner has scientifically proven greater accuracy* for your clinical orthodontic needs.
(4) For Invisalign record-taking cases only. Based on a survey in September 2023 of n=22 users who participated in a global limited market release, working with iTero Lumina™ intraoral scanner for an average period of 6 months, representing both Invisalign trained general practitioners and orthodontists in NA, EU and APAC, who were presented with a 4 point level of agreement scale from strongly agree to strongly disagree with the following statements: “iTero Lumina™ intraoral scanner 3D model is comparable to that of an intraoral photo.” and “iTero Lumina™ intraoral scanner photorealistic scans enable orthodontic clinical assessment the same way intraoral photos do.” and “iTero Lumina™ intraoral scanner 3D model’s superior 3D model eliminates the need to take intraoral photos.” and “iTero Lumina™ intraoral scanner 3D model’s superior 3D model boosts patient engagement.”*
*Data on file at Align Technology, as of November 15, 2023.
(5) For more information, please see the tables captioned "Unaudited GAAP to Non-GAAP Reconciliation."

Financial Summary - Fourth Quarter Fiscal 2023

 

Q4'23

 

Q3'23

 

Q4'22

 

Q/Q Change

 

Y/Y Change

Clear Aligner Shipments*

592,635

 

602,335

 

596,155

 

(1.6)%

 

(0.6)%

GAAP

 

 

 

 

 

 

 

 

 

Net Revenues

$956.7M

 

$960.2M

 

$901.5M

 

(0.4)%

 

+6.1%

Clear Aligner

$781.9M

 

$794.9M

 

$731.7M

 

(1.6)%

 

+6.9%

Imaging Systems and CAD/CAM Services

$174.8M

 

$165.3M

 

$169.9M

 

+5.8%

 

+2.9%

Net Income

$124.0M

 

$121.4M

 

$41.8M

 

+2.1%

 

+196.9%

Diluted EPS

$1.64

 

$1.58

 

$0.54

 

+$0.06

 

+$1.10

Non-GAAP

 

 

 

 

 

 

 

 

 

Net Income(6)

$183.5M

 

$164.3M

 

$134.2M

 

+11.7%

 

+36.7%

Diluted EPS(6)

$2.42

 

$2.14

 

$1.73

 

+$0.28

 

+$0.69

Financial Summary - Fiscal 2023

 

2023

 

2022

 

Y/Y Change

Clear Aligner Shipments*

2,408,520

 

2,398,370

 

+0.4%

GAAP

 

 

 

 

 

Net Revenues

$3,862.3M

 

$3,734.6M

 

+3.4%

Clear Aligner

$3,199.3M

 

$3,072.6M

 

+4.1%

Imaging Systems and CAD/CAM Services

$662.9M

 

$662.1M

 

+0.1%

Net Income

$445.1M

 

$361.6M

 

+23.1%

Diluted EPS

$5.81

 

$4.61

 

+$1.20

Non-GAAP

 

 

 

 

 

Net Income(6)

$659.2M

 

$608.2M

 

+8.4%

Diluted EPS(6)

$8.61

 

$7.76

 

+$0.85

Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding.
*Clear Aligner shipments include Doctor Subscription Program Touch-Up cases.

(6) In Q4'22, we changed our methodology for the computation of the non-GAAP effective tax rate to a long-term projected tax rate and have given effect to the new methodology from January 1, 2022.

As of December 31, 2023, we had $980.8 million in cash, cash equivalents and short-term and long-term marketable securities compared to over $1.3 billion as of September 30, 2023. As of December 31, 2023, we had $300.0 million available under a revolving line of credit.

Commenting on Align's 2023 results, Align Technology CFO and EVP Global Finance, John Morici said, "I am pleased with our fourth quarter and fiscal 2023 results, and I am especially proud of our continued focused execution of our product roadmap and innovation pipeline. We are committed to delivering on our strategic growth drivers of International Expansion, Patient Demand, Orthodontist Utilization, and GP Dentist Treatment to extend our leadership in digital orthodontics and dentistry. I believe that the next wave of innovation that we are introducing into the market will further differentiate Align and allow us to increase our share of the large untapped market opportunity of 22 million annual orthodontic case starts as well as the additional 600 million consumers who could benefit from a healthy beautiful smile using Invisalign® clear aligners."

Q4'23 Announcement Highlights

  • On November 6, 2023, we announced the opening of Align's 2024 Annual Research Award Program to support clinical and scientific dental research in universities across the globe. Under the program, up to $300,000 is being awarded to university faculty for scientific and technological research initiatives to advance patient care in the fields of orthodontics and dentistry. Align Technology’s Research Award Program has funded approximately $3 million in research since the program’s inception in 2010.
  • On December 5, 2023, we announced the appointments to Align's board of directors of Mojdeh Poul, former EVP and Group President of 3M Health Care, and Kevin Conroy, President, Chief Executive Officer, and Chairman of the Board of Exact Sciences.
  • On December 13, 2023, we announced that Health Canada issued an updated medical device license to Align for the Invisalign® Palatal Expander system* ("IPE"). The updated license for broad patient applicability includes growing children, teens, and adults (with surgery or other techniques).
  • On December 18, 2023, we announced that the U.S. Food and Drug Administration ("FDA") cleared Align’s IPE system* for commercial availability in the U.S. The FDA 510(k) clearance is for broad patient applicability, including growing children, teens, and adults (with surgery or other techniques). The IPE system is available on a limited basis in Canada and the U.S. It is expected to be available in other markets pending future applicable regulatory approvals.
  • On January 2, 2024, Align completed the acquisition of privately-held Cubicure GmbH, a pioneer in direct 3D printing solutions for polymer additive manufacturing that develops, produces, and distributes innovative materials, equipment, and processes for novel 3D printing solutions.

*Based on a survey in August 2023 in Canada of 10 Invisalign trained orthodontists who participated in the IPE system Technical Design Assessment and have treated at least 1 patient age 6-11 years with IPE. Data on file at Align Technology, Inc. as of October 30, 2023.

Q4'23 Stock Repurchases

In October 2023, we purchased approximately 1.0 million shares of our common stock at an average price of $190.56 per share through a $250.0 million Accelerated Share Repurchase* and, in November and December 2023, we purchased approximately 466 thousand shares of our common stock at an average price of $214.81 per share through $100.0 million open market repurchase, both under Align's current $1.0 billion stock repurchase program.

We have $650.0 million remaining available for repurchase of our common stock under this stock repurchase program.

*Contract was open, as of Dec. 31, 2023.

Fiscal 2024 Business Outlook

Turning to our outlook, assuming no circumstances occur beyond our control, we provide the following framework for Q1 and fiscal 2024:

First quarter 2024 outlook:

  • For Q1’24, we expect our worldwide revenues to be in the range of $960M to $980M, up slightly from Q4’23.
  • We expect clear aligner volume and ASPs to be up slightly sequentially.
  • We expect systems and services revenue to be down slightly sequentially, although less than the historical seasonal decline given the launch of the iTero Lumina™ for ortho workflows in Q1’24.
  • We expect our Q1’24 GAAP operating margin and non-GAAP operating margin to be slightly above Q1’23 GAAP operating margin and non-GAAP operating margin, respectively.

Full year 2024 outlook:

  • We expect our 2024 total revenues to be up mid-single digits over 2023.
  • We expect our 2024 clear aligner and systems and services revenues to grow year over year in the same approximate range as 2024 total revenues.
  • We expect our 2024 clear aligner ASPs to be up slightly year-over-year, primarily due to price increases and favorable foreign exchange, partially offset by a higher mix of non-comprehensive products which have lower ASPs.
  • We expect our full year 2024 GAAP operating margin and non-GAAP operating margin to be slightly above the 2023 GAAP operating margin and non-GAAP operating margin, respectively.
  • For 2024, we expect investments in capital expenditures to be approximately $100M. Capital expenditures are expected to primarily relate to building construction and improvements as well as manufacturing capacity in support of our continued expansion.

Align Web Cast and Conference Call

We will host a conference call today, January 31, 2024, at 4:30 p.m. ET, 2:30 p.m. MT, to review our fourth quarter and full year 2023 results, discuss future operating trends, and our business outlook. The conference call will also be webcast live via the Internet. To access the webcast, go to the "Events & Presentations" section under Company Information on Align's Investor Relations website at http://investor.aligntech.com. To access the conference call, participants may register for the call by clicking here. Once registered, participants will receive an email with dial-in number and unique PIN number to access the live event. An archived audio webcast will be available 2 hours after the call's conclusion and will remain available for one month.

About Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States ("GAAP"), we may provide investors with certain non-GAAP financial measures which may include constant currency net revenues, constant currency gross profit, constant currency gross margin, constant currency income from operations, constant currency operating margin, gross profit, gross margin, operating expenses, income from operations, operating margin, interest income and other income (expense), net, net income before provision for income taxes, provision for income taxes, effective tax rate, net income and/or diluted net income per share, which excludes certain items that may not be indicative of our fundamental operating performance including, foreign currency exchange rate impacts and discrete cash and non-cash charges or gains that are included in the most directly comparable GAAP measure. In Q4'22, we changed to a long-term non-GAAP effective tax rate in our computation of the non-GAAP income tax provision to provide better consistency across reporting periods. Our previous methodology for calculating our non-GAAP effective tax rate included certain non-recurring and period-specific items, that produced fluctuating effective tax rates that management does not believe are reflective of the Company's long-term effective tax rate. We have given effect to this new methodology effective January 1, 2022. Unless otherwise indicated, when we refer to non-GAAP financial measures they will exclude the effects of stock-based compensation, amortization of certain acquired intangibles, restructuring and other charges, acquisition-related costs, and associated tax impacts.

Our management believes that the use of certain non-GAAP financial measures provides meaningful supplemental information regarding our recurring core operating performance. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

There are limitations to using non-GAAP financial measures as they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which charges are excluded from the non-GAAP financial measures. We compensate for these limitations by analyzing current and future results on a GAAP as well as a non-GAAP basis and also by providing GAAP measures in our public disclosures. The presentation of non-GAAP financial information is meant to be considered in addition to, not as a substitute for or in isolation from, the directly comparable financial measures prepared in accordance with GAAP. We urge investors to review the reconciliation of our GAAP financial measures to the comparable non-GAAP financial measures included herein and not to rely on any single financial measure to evaluate our business. For more information on these non-GAAP financial measures, please see the tables captioned "Unaudited GAAP to Non-GAAP Reconciliation."

About Align Technology, Inc.

Align Technology designs and manufactures the Invisalign® system, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 256 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide. Over the past 26 years, Align has helped doctors treat approximately 17 million patients with the Invisalign system and is driving the evolution in digital dentistry through the Align Digital Platform™, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about the iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit www.exocad.com.

Invisalign, iTero, exocad, Align, Align Digital Platform, iTero Element and iTero-exocad Connector are trademarks of Align Technology, Inc.

Forward-Looking Statements

This news release, including the tables below, contains forward-looking statements, including statements of beliefs and expectations regarding anticipated capital expenditures, clear aligner volumes, clear aligner ASPs, iTero scanner and services revenue, total revenues and operating margin, customer and consumer demand trends and market opportunities, our ability to successfully control our business and operations and pursue our strategic growth drivers, our expectations regarding the timing and impact of new products and technologies, our beliefs for the impacts of our stock repurchase programs and our ability to generate cash flow, and our beliefs regarding the trajectory of our business. Forward-looking statements contained in this news release relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements reflect our best judgments based on currently known facts and circumstances and are subject to risks, uncertainties, and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement.

Factors that might cause such a difference include, but are not limited to:

  • macroeconomic conditions, including inflation, fluctuations in currency exchange rates, rising interest rates, market volatility, weakness in general economic conditions and recessions and the impact of efforts by central banks and federal, state and local governments to combat inflation and recession;
  • customer and consumer purchasing behavior and changes in consumer spending habits as a result of, among other things, prevailing macro-economic conditions, levels of employment, salaries and wages, debt obligations, discretionary income, inflationary pressure, declining consumer confidence, and military conflicts in Ukraine and the Middle East;
  • the economic and geopolitical ramifications of the hostilities in the Middle East as well as the military conflict in Ukraine, including sanctions, retaliatory sanctions, nationalism, supply chain disruptions and other consequences, any of which may or will continue to adversely impact our operations and assets and our research and development activities;
  • variations in our product mix, product adoption and selling prices regionally and globally;
  • competition from existing and new competitors;
  • declines in, or the slowing of growth of, sales of our clear aligners or intraoral scanners domestically and/or internationally and the impact either would have on the adoption of Invisalign products;
  • the timing and availability and cost of raw materials, components, products and other shipping and supply chain constraints, disruptions or costs;
  • unexpected or rapid changes in the growth or decline of our domestic and/or international markets;
  • rapidly evolving and groundbreaking advances that fundamentally alter the dental industry or the way new and existing customers market and provide products and services to consumers;
  • the ability to protect and enforce our intellectual property rights;
  • continued compliance with regulatory requirements;
  • the willingness and ability of our customers to maintain and/or increase product utilization;
  • the possibility that the development and release of new products or enhancements to existing products do not proceed in accordance with the anticipated timeline or may themselves contain bugs, errors or defects in software or hardware requiring remediation and that the market for the sale of these new or enhanced products may not develop as expected;
  • a tougher consumer demand environment in China generally, especially for manufacturers and service providers whose headquarters or primary operations are not based in China;
  • the risks relating to our ability to sustain or increase profitability or revenue growth in future periods (or minimize declines) while controlling expenses;
  • expansion of our business and products;
  • the impact of excess or constrained capacity at our manufacturing and treat operations facilities and pressure on our internal systems and personnel;
  • the compromise of our systems or networks, including any customer and/or patient data contained therein, for any reason;
  • the timing of case submissions from our doctor customers within a quarter as well as an increased manufacturing costs per case;
  • foreign operational, political, military and other risks relating to our operations; and
  • the loss of key personnel, labor shortages or work stoppages for us or our suppliers.

The foregoing and other risks are detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including, but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission ("SEC") on February 27, 2023 and our latest Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, which was filed with the SEC on November 3, 2023. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

ALIGN TECHNOLOGY, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)

 

 

Three Months Ended
December 31,

 

Year Ended
December 31,

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Net revenues

 

$

956,726

 

 

$

901,515

 

 

$

3,862,260

 

 

$

3,734,635

 

Cost of net revenues

 

 

287,202

 

 

 

283,814

 

 

 

1,155,397

 

 

 

1,100,860

 

Gross profit

 

 

669,524

 

 

 

617,701

 

 

 

2,706,863

 

 

 

2,633,775

 

Operating expenses:

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

402,503

 

 

 

410,067

 

 

 

1,703,379

 

 

 

1,674,469

 

Research and development

 

 

82,160

 

 

 

83,520

 

 

 

346,830

 

 

 

305,258

 

Restructuring and other charges

 

 

13,316

 

 

 

11,453

 

 

 

13,316

 

 

 

11,453

 

Total operating expenses

 

 

497,979

 

 

 

505,040

 

 

 

2,063,525

 

 

 

1,991,180

 

Income from operations

 

 

171,545

 

 

 

112,661

 

 

 

643,338

 

 

 

642,595

 

Interest income and other income (expense), net:

 

 

 

 

 

 

 

 

Interest income

 

 

4,978

 

 

 

2,760

 

 

 

17,258

 

 

 

5,367

 

Other income (expense), net

 

 

(3,643

)

 

 

(100

)

 

 

(19,392

)

 

 

(48,905

)

Total interest income and other income (expense), net

 

 

1,335

 

 

 

2,660

 

 

 

(2,134

)

 

 

(43,538

)

Net income before provision for income taxes

 

 

172,880

 

 

 

115,321

 

 

 

641,204

 

 

 

599,057

 

Provision for income taxes

 

 

48,866

 

 

 

73,546

 

 

 

196,151

 

 

 

237,484

 

Net income

 

$

124,014

 

 

$

41,775

 

 

$

445,053

 

 

$

361,573

 

 

 

 

 

 

 

 

 

 

Net income per share:

 

 

 

 

 

 

 

 

Basic

 

$

1.64

 

 

$

0.54

 

 

$

5.82

 

 

$

4.62

 

Diluted

 

$

1.64

 

 

$

0.54

 

 

$

5.81

 

 

$

4.61

 

Shares used in computing net income per share:

 

 

 

 

 

 

 

 

Basic

 

 

75,703

 

 

 

77,541

 

 

 

76,426

 

 

 

78,190

 

Diluted

 

 

75,802

 

 

 

77,683

 

 

 

76,568

 

 

 

78,420

 

ALIGN TECHNOLOGY, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)

 

 

December 31,
2023

 

December 31,
2022

ASSETS

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

937,438

 

$

942,050

Marketable securities, short-term

 

 

35,304

 

 

57,534

Accounts receivable, net

 

 

903,424

 

 

859,685

Inventories

 

 

296,902

 

 

338,752

Prepaid expenses and other current assets

 

 

273,550

 

 

226,370

Total current assets

 

 

2,446,618

 

 

2,424,391

 

 

 

 

 

Marketable securities, long-term

 

 

8,022

 

 

41,978

Property, plant and equipment, net

 

 

1,290,863

 

 

1,231,855

Operating lease right-of-use assets, net

 

 

117,999

 

 

118,880

Goodwill

 

 

419,530

 

 

407,551

Intangible assets, net

 

 

82,118

 

 

95,720

Deferred tax assets

 

 

1,590,045

 

 

1,571,746

Other assets

 

 

128,682

 

 

55,826

 

 

 

 

 

Total assets

 

$

6,083,877

 

$

5,947,947

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

113,125

 

$

127,870

Accrued liabilities

 

 

525,780

 

 

454,374

Deferred revenues

 

 

1,427,706

 

 

1,343,643

Total current liabilities

 

 

2,066,611

 

 

1,925,887

 

 

 

 

 

Income tax payable

 

 

116,744

 

 

124,393

Operating lease liabilities

 

 

96,968

 

 

100,334

Other long-term liabilities

 

 

173,065

 

 

195,975

Total liabilities

 

 

2,453,388

 

 

2,346,589

 

 

 

 

 

Total stockholders’ equity

 

 

3,630,489

 

 

3,601,358

 

 

 

 

 

Total liabilities and stockholders’ equity

 

$

6,083,877

 

$

5,947,947

ALIGN TECHNOLOGY, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

 

 

Year Ended
December 31,

 

 

 

2023

 

 

 

2022

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

Net cash provided by operating activities

 

$

785,776

 

 

$

568,732

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

Net cash used in investing activities

 

 

(195,943

)

 

 

(213,316

)

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

Net cash used in financing activities

 

 

(598,340

)

 

 

(501,686

)

 

 

 

 

 

Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash

 

 

4,671

 

 

 

(11,514

)

Net (decrease) increase in cash, cash equivalents, and restricted cash

 

 

(3,836

)

 

 

(157,784

)

Cash, cash equivalents, and restricted cash at beginning of the period

 

 

942,355

 

 

 

1,100,139

 

Cash, cash equivalents, and restricted cash at end of the period

 

$

938,519

 

 

$

942,355

 

ALIGN TECHNOLOGY, INC.
INVISALIGN BUSINESS METRICS

 

 

Q1

 

Q2

 

Q3

 

Q4

 

Q1

 

Q2

 

Q3

 

Q4

 

 

2022

 

2022

 

2022

 

2022

 

2023

 

2023

 

2023

 

2023

Number of Invisalign Trained Doctors Cases Were Shipped To

 

 

82,445

 

 

82,290

 

 

84,430

 

 

82,895

 

 

82,730

 

 

83,440

 

 

85,195

 

 

83,700

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Invisalign Trained Doctor Utilization Rates*:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

North America

 

 

9.4

 

 

9.6

 

 

9.2

 

 

9.2

 

 

9.5

 

 

9.8

 

 

9.6

 

 

9.1

North American Orthodontists

 

 

27.8

 

 

28.1

 

 

27.6

 

 

26.7

 

 

28.7

 

 

29.2

 

 

28.8

 

 

25.9

North American GP Dentists

 

 

5.0

 

 

5.1

 

 

4.8

 

 

5.0

 

 

4.9

 

 

5.2

 

 

4.9

 

 

5.0

International

 

 

6.4

 

 

6.4

 

 

6.0

 

 

6.5

 

 

6.2

 

 

6.6

 

 

6.1

 

 

6.5

Total Utilization Rates**

 

 

7.3

 

 

7.4

 

 

7.0

 

 

7.2

 

 

7.1

 

 

7.5

 

 

7.1

 

 

7.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clear Aligner Revenue Per Case Shipment***:

 

$

1,335

 

$

1,315

 

$

1,245

 

$

1,225

 

$

1,335

 

$

1,335

 

$

1,320

 

$

1,320

* # of cases shipped / # of doctors to whom cases were shipped
** LATAM utilization rate is not separately disclosed but included in the total utilization rates
*** Clear Aligner revenues / Case shipments as of Q4'23
Note: During the third quarter of 2023, we began including Touch Up cases revenues that were previously included in
Non-Case revenues and have recast business metrics for the periods presented above accordingly.

ALIGN TECHNOLOGY, INC.
STOCK-BASED COMPENSATION
(in thousands)

 

 

Q1

 

Q2

 

Q3

 

Q4

 

Fiscal

 

Q1

 

Q2

 

Q3

 

Q4

 

Fiscal

 

 

2022

 

2022

 

2022

 

2022

 

2022

 

2023

 

2023

 

2023

 

2023

 

2023

Stock-based Compensation (SBC):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SBC included in Gross Profit

 

$

1,514

 

$

1,614

 

$

1,651

 

$

1,659

 

$

6,438

 

$

1,807

 

$

1,901

 

$

1,974

 

$

1,780

 

$

7,462

SBC included in Operating Expenses

 

 

30,107

 

 

32,526

 

 

31,267

 

 

33,029

 

 

126,929

 

 

35,928

 

 

35,959

 

 

37,628

 

 

37,049

 

$

146,564

Total SBC

 

$

31,621

 

$

34,140

 

$

32,918

 

$

34,688

 

$

133,367

 

$

37,735

 

$

37,860

 

$

39,602

 

$

38,829

 

$

154,026

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION+
CONSTANT CURRENCY NET REVENUES
(in thousands, except percentages)

Sequential constant currency analysis:

 

 

Three Months Ended

 

 

 

 

December 31,
2023

 

September 30,
2023

 

Impact % of
Revenue

GAAP net revenues

 

$

956,726

 

$

960,214

 

 

Constant currency impact (1)

 

 

12,782

 

 

 

1.3

%

Constant currency net revenues (1)

 

$

969,508

 

 

 

 

 

 

 

 

 

 

 

GAAP Clear Aligner net revenues

 

$

781,912

 

$

794,939

 

 

Clear Aligner constant currency impact (1)

 

 

10,711

 

 

 

1.4

%

Clear Aligner constant currency net revenues (1)

 

$

792,623

 

 

 

 

 

 

 

 

 

 

 

GAAP Imaging Systems and CAD/CAM Services net revenues

 

$

174,814

 

$

165,275

 

 

Imaging Systems and CAD/CAM Services constant currency impact (1)

 

 

2,071

 

 

 

1.2

%

Imaging Systems and CAD/CAM Services constant currency net revenues (1)

 

$

176,885

 

 

 

 

Year-over-year constant currency analysis:

 

 

Three Months Ended

December 31,

 

 

 

 

 

2023

 

 

 

2022

 

Impact % of Revenue

GAAP net revenues

 

$

956,726

 

 

$

901,515

 

 

Constant currency impact (1)

 

 

(13,818

)

 

 

 

(1.5

) %

Constant currency net revenues (1)

 

$

942,908

 

 

 

 

 

 

 

 

 

 

 

 

GAAP Clear Aligner net revenues

 

$

781,912

 

 

$

731,654

 

 

Clear Aligner constant currency impact (1)

 

 

(11,957

)

 

 

 

(1.6

) %

Clear Aligner constant currency net revenues (1)

 

$

769,955

 

 

 

 

 

 

 

 

 

 

 

 

GAAP Imaging Systems and CAD/CAM Services net revenues

 

$

174,814

 

 

$

169,861

 

 

Imaging Systems and CAD/CAM Services constant currency impact (1)

 

 

(1,860

)

 

 

 

(1.1

) %

Imaging Systems and CAD/CAM Services constant currency net revenues (1)

 

$

172,954

 

 

 

 

 

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED+
CONSTANT CURRENCY NET REVENUES CONTINUED
(in thousands, except percentages)

Current year versus prior year constant currency analysis:

 

 

Year Ended December 31,

 

 

 

 

 

2023

 

 

2022

 

Impact % of
Revenue

GAAP net revenues

 

$

3,862,260

 

$

3,734,635

 

 

Constant currency impact (1)

 

 

36,267

 

 

 

0.9

%

Constant currency net revenues (1)

 

$

3,898,527

 

 

 

 

 

 

 

 

 

 

 

GAAP Clear Aligner net revenues

 

$

3,199,329

 

$

3,072,585

 

 

Clear Aligner constant currency impact (1)

 

 

29,683

 

 

 

0.9

%

Clear Aligner constant currency net revenues (1)

 

$

3,229,012

 

 

 

 

 

 

 

 

 

 

 

GAAP Imaging Systems and CAD/CAM Services net revenues

 

$

662,931

 

$

662,050

 

 

Imaging Systems and CAD/CAM Services constant currency impact (1)

 

 

6,583

 

 

 

1.0

%

Imaging Systems and CAD/CAM Services constant currency net revenues (1)

 

$

669,514

 

 

 

 

Note:
(1) We define constant currency net revenues as total net revenues excluding the effect of foreign exchange rate movements and use it to determine the percentage for the constant currency impact on net revenues on a sequential, year-over-year and current year versus prior year basis. Constant currency impact in dollars is calculated by translating the current period GAAP net revenues using the foreign currency exchange rates that were in effect during the previous comparable period and subtracting it by the current period GAAP net revenues. The percentage for the constant currency impact on net revenues is calculated by dividing the constant currency impact in dollars (numerator) by constant currency net revenues in dollars (denominator).
(+) Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Refer to "About Non-GAAP Financial Measures" section of press release.

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED+
CONSTANT CURRENCY GROSS PROFIT AND GROSS MARGIN
(in thousands, except percentages)

Sequential constant currency analysis:

 

 

Three Months Ended

 

 

December 31,
2023

 

September 30,
2023

GAAP gross profit

 

$

669,524

 

$

663,076

Constant currency impact on net revenues

 

 

12,782

 

 

Constant currency gross profit

 

$

682,306

 

 

 

 

Three Months Ended

 

 

December 31,
2023

 

September 30,
2023

GAAP gross margin

 

70.0

%

 

69.1

%

Gross margin constant currency impact (1)

 

0.4

 

 

 

Constant currency gross margin (1)

 

70.4

%

 

 

Year-over-year constant currency analysis:

 

 

Three Months Ended

December 31,

 

 

 

2023

 

 

 

2022

GAAP gross profit

 

$

669,524

 

 

$

617,701

Constant currency impact on net revenues

 

 

(13,805

)

 

 

Constant currency gross profit

 

$

655,719

 

 

 

 

 

Three Months Ended
December 30,

 

 

2023

 

 

2022

 

GAAP gross margin

 

70.0

%

 

68.5

%

Gross margin constant currency impact (1)

 

(0.4

)

 

 

Constant currency gross margin (1)

 

69.5

%

 

 

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED+
CONSTANT CURRENCY GROSS PROFIT AND GROSS MARGIN
(in thousands, except percentages)

Current year versus prior year constant currency analysis:

 

 

Year Ended December 31,

 

 

2023

 

2022

GAAP gross profit

 

$

2,706,863

 

$

2,633,775

Constant currency impact on net revenues

 

 

36,310

 

 

Constant currency gross profit

 

$

2,743,174

 

 

 

 

Year Ended December 31,

 

 

2023

 

2022

GAAP gross margin

 

70.1

%

 

70.5

%

Constant currency impact on net revenues(1)

 

0.3

 

 

 

Constant currency gross margin(1)

 

70.4

%

 

 

Note:

(1) We define constant currency gross margin as constant currency gross profit as a percentage of constant currency net revenues. Gross margin constant currency impact is the increase or decrease in constant currency gross margin compared to the GAAP gross margin.
(+) Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Refer to "About Non-GAAP Financial Measures" section of press release.

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED+
CONSTANT CURRENCY INCOME FROM OPERATIONS AND OPERATING MARGIN
(in thousands, except percentages)

Sequential constant currency analysis:

 

 

Three Months Ended

 

 

December 31,
2023

 

September 30,
2023

GAAP income from operations

 

$

171,545

 

$

166,346

Income from operations constant currency impact (1)

 

 

8,226

 

 

Constant currency income from operations (1)

 

$

179,771

 

 

 

 

Three Months Ended

 

 

December 31,
2023

 

September 30,
2023

GAAP operating margin

 

17.9

%

 

17.3

%

Operating margin constant currency impact (2)

 

0.6

 

 

 

Constant currency operating margin (2)

 

18.5

%

 

 

Year-over-year constant currency analysis:

 

 

Three Months Ended

December 31,

 

 

 

2023

 

 

 

2022

GAAP income from operations

 

$

171,545

 

 

$

112,661

Income from operations constant currency impact (1)

 

 

(8,305

)

 

 

Constant currency income from operations (1)

 

$

163,240

 

 

 

 

 

Three Months Ended

December 31,

 

 

2023

 

 

2022

 

GAAP operating margin

 

17.9

%

 

12.5

%

Operating margin constant currency impact (2)

 

(0.6

)

 

 

Constant currency operating margin (2)

 

17.3

%

 

 

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED+
CONSTANT CURRENCY INCOME FROM OPERATIONS AND OPERATING MARGIN CONTINUED
(in thousands, except percentages)

Current year versus prior year constant currency analysis:

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

GAAP income from operations

 

$

643,338

 

$

642,595

Income from operations constant currency impact (1)

 

 

31,988

 

 

Constant currency income from operations (1)

 

$

675,326

 

 

 

 

Year Ended December 31,

 

 

2023

 

 

2022

 

GAAP operating margin

 

16.7

%

 

17.2

%

Operating margin constant currency impact (2)

 

0.7

 

 

 

Constant currency operating margin (2)

 

17.3

%

 

 

Notes:

(1) We define constant currency income from operations as GAAP income from operations excluding the effect of foreign exchange rate movements for GAAP net revenues and operating expenses on a sequential, year-over-year and current year versus prior year basis. Constant currency impact in dollars is calculated by translating the current period GAAP net revenues and operating expenses using the foreign currency exchange rates that were in effect during the previous comparable period and subtracting it by the current period GAAP net revenues and operating expenses.
(2) We define constant currency operating margin as constant currency income from operations as a percentage of constant currency net revenues. Operating margin constant currency impact is the increase or decrease in constant currency operating margin compared to the GAAP operating margin.
(+) Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Refer to "About Non-GAAP Financial Measures" section of press release.

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED+
FINANCIAL MEASURES OTHER THAN CONSTANT CURRENCY
(in thousands, except per share data)

 

 

Three Months Ended
December 31,

 

Year Ended
December 31,

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

GAAP gross profit

 

$

669,524

 

 

$

617,701

 

 

$

2,706,863

 

 

$

2,633,775

 

Stock-based compensation

 

 

1,780

 

 

 

1,659

 

 

 

7,462

 

 

 

6,438

 

Amortization of intangibles (1)

 

 

2,773

 

 

 

2,610

 

 

 

11,182

 

 

 

10,134

 

Restructuring charges (2)

 

 

673

 

 

 

2,866

 

 

 

673

 

 

 

2,866

 

Non-GAAP gross profit

 

$

674,750

 

 

$

624,836

 

 

$

2,726,180

 

 

$

2,653,213

 

 

 

 

 

 

 

 

 

 

GAAP gross margin

 

 

70.0

%

 

 

68.5

%

 

 

70.1

%

 

 

70.5

%

Non-GAAP gross margin

 

 

70.5

%

 

 

69.3

%

 

 

70.6

%

 

 

71.0

%

 

 

 

 

 

 

 

 

 

GAAP total operating expenses

 

$

497,979

 

 

$

505,040

 

 

$

2,063,525

 

 

$

1,991,180

 

Stock-based compensation

 

 

(37,049

)

 

 

(33,029

)

 

 

(146,564

)

 

 

(126,929

)

Amortization of intangibles (1)

 

 

(866

)

 

 

(810

)

 

 

(3,497

)

 

 

(3,417

)

Restructuring and other charges (2)

 

 

(13,316

)

 

 

(11,453

)

 

 

(13,316

)

 

 

(11,453

)

Non-GAAP total operating expenses

 

$

446,748

 

 

$

459,748

 

 

$

1,900,148

 

 

$

1,849,381

 

 

 

 

 

 

 

 

 

 

GAAP income from operations

 

$

171,545

 

 

$

112,661

 

 

$

643,338

 

 

$

642,595

 

Stock-based compensation

 

 

38,829

 

 

 

34,688

 

 

 

154,026

 

 

 

133,367

 

Amortization of intangibles (1)

 

 

3,639

 

 

 

3,420

 

 

 

14,679

 

 

 

13,551

 

Restructuring and other charges (2)

 

 

13,989

 

 

 

14,319

 

 

 

13,989

 

 

 

14,319

 

Non-GAAP income from operations

 

$

228,002

 

 

$

165,088

 

 

$

826,032

 

 

$

803,832

 

 

 

 

 

 

 

 

 

 

GAAP operating margin

 

 

17.9

%

 

 

12.5

%

 

 

16.7

%

 

 

17.2

%

Non-GAAP operating margin

 

 

23.8

%

 

 

18.3

%

 

 

21.4

%

 

 

21.5

%

 

 

 

 

 

 

 

 

 

GAAP net income before provision for income taxes

 

$

172,880

 

 

$

115,321

 

 

$

641,204

 

 

$

599,057

 

Stock-based compensation

 

 

38,829

 

 

 

34,688

 

 

 

154,026

 

 

 

133,367

 

Amortization of intangibles (1)

 

 

3,639

 

 

 

3,420

 

 

 

14,679

 

 

 

13,551

 

Restructuring and other charges (2)

 

 

13,989

 

 

 

14,319

 

 

 

13,989

 

 

 

14,319

 

Non-GAAP net income before provision for income taxes

 

$

229,337

 

 

$

167,748

 

 

$

823,898

 

 

$

760,294

 

ALIGN TECHNOLOGY, INC.
UNAUDITED GAAP TO NON-GAAP RECONCILIATION CONTINUED
FINANCIAL MEASURES OTHER THAN CONSTANT CURRENCY CONTINUED
(in thousands, except per share data)

 

 

Three Months Ended
December 31,

 

Year Ended
December 31,

 

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

GAAP provision for income taxes

 

$

48,866

 

 

$

73,546

 

 

$

196,151

 

 

$

237,484

 

Tax impact on non-GAAP adjustments (3)

 

 

(2,998

)

 

 

(39,997

)

 

 

(31,415

)

 

 

(85,426

)

Non-GAAP provision for income taxes (3)

 

$

45,868

 

 

$

33,549

 

 

$

164,736

 

 

$

152,058

 

 

 

 

 

 

 

 

 

 

GAAP effective tax rate

 

 

28.3

%

 

 

63.8

%

 

 

30.6

%

 

 

39.6

%

Non-GAAP effective tax rate (3)

 

 

20.0

%

 

 

20.0

%

 

 

20.0

%

 

 

20.0

%

 

 

 

 

 

 

 

 

 

GAAP net income

 

$

124,014

 

 

$

41,775

 

 

$

445,053

 

 

$

361,573

 

Stock-based compensation

 

 

38,829

 

 

 

34,688

 

 

 

154,026

 

 

 

133,367

 

Amortization of intangibles (1)

 

 

3,639

 

 

 

3,420

 

 

 

14,679

 

 

 

13,551

 

Restructuring and other charges (2)

 

 

13,989

 

 

 

14,319

 

 

 

13,989

 

 

 

14,319

 

Tax impact on non-GAAP adjustments (3)

 

 

2,998

 

 

 

39,997

 

 

 

31,415

 

 

 

85,426

 

Non-GAAP net income (3)

 

$

183,469

 

 

$

134,199

 

 

$

659,162

 

 

$

608,236

 

 

 

 

 

 

 

 

 

 

GAAP diluted net income per share

 

$

1.64

 

 

$

0.54

 

 

$

5.81

 

 

$

4.61

 

Non-GAAP diluted net income per share (3)

 

$

2.42

 

 

$

1.73

 

 

$

8.61

 

 

$

7.76

 

 

 

 

 

 

 

 

 

 

Shares used in computing diluted net income per share

 

 

75,802

 

 

 

77,683

 

 

 

76,568

 

 

 

78,420

 

Notes:
(1) Amortization of intangible assets related to certain acquisitions
(2) During the fourth quarters of 2022 and 2023, we initiated restructuring plans to increase efficiencies across the organization and lower the overall cost structure. Restructuring charges recorded to Cost of net revenues and operating expenses primarily related to post-employment benefits, lease termination charges and asset impairments in 2022 and post-employment benefits in 2023.
(3) In Q4'22, we changed our methodology for the computation of the non-GAAP effective tax rate to a long-term projected tax rate and have given effect to the new methodology from January 1, 2022.
(+) Changes and percentages are based on actual values. Certain tables may not sum or recalculate due to rounding. Refer to "About Non-GAAP Financial Measures" section of press release.

ALIGN TECHNOLOGY, INC.
Q1 2024 OUTLOOK - GAAP TO NON-GAAP RECONCILIATION

GAAP Operating Margin

 

slightly above 14.2%

Stock-based compensation

 

~4.0%

Amortization of intangibles (1)

 

~0.4%

Non-GAAP Operating Margin

 

slightly above 18.5%

ALIGN TECHNOLOGY, INC.
FISCAL 2024 OUTLOOK - GAAP TO NON-GAAP RECONCILIATION

GAAP Operating Margin

 

slightly above 16.7%

Stock-based compensation

 

~4.4%

Amortization of intangibles (1)

 

~0.4%

Non-GAAP Operating Margin

 

slightly above 21.4%

(1) Amortization of intangible assets related to certain acquisitions

Refer to "About Non-GAAP Financial Measures" section of press release.

Align Technology

Madelyn Valente

(909) 833-5839

mvalente@aligntech.com

Zeno Group

Sarah Johnson

(828) 551-4201

sarah.johnson@zenogroup.com

Source: Align Technology, Inc.

FAQ

What were Align's total revenues in 2023?

Align's 2023 total revenues were $3.9 billion.

How many Invisalign patients did Align achieve in 2023?

Align achieved 17 million Invisalign patients in 2023.

What is the operating margin for 2023?

The 2023 operating margin was 16.7%, with non-GAAP operating margin of 21.4%.

What was the impact of foreign exchange on 2023 revenues?

2023 revenues were unfavorably impacted by foreign exchange of approximately $36.3 million compared to 2022.

How many shares of common stock did Align repurchase in 2023?

Align repurchased $600 million of common stock in 2023.

What new product did Align unveil recently?

Align unveiled the iTero Lumina intraoral scanner with significant improvements in scanning capabilities.

Align Technology Inc

NASDAQ:ALGN

ALGN Rankings

ALGN Latest News

ALGN Stock Data

15.94B
69.72M
6.6%
89.99%
4.01%
Medical Instruments & Supplies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
TEMPE